156 related articles for article (PubMed ID: 36445410)
1. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
Silk AW; O'Day SJ; Kaufman HL; Bryan J; Norrell JT; Imbergamo C; Portal D; Zambrano-Acosta E; Palmeri M; Fein S; Wu C; Guerreiro L; Medina D; Bommareddy PK; Zloza A; Fox BA; Ballesteros-Merino C; Ren Y; Shafren D; Grose M; Vieth JA; Mehnert JM
Cancer Immunol Immunother; 2023 Jun; 72(6):1405-1415. PubMed ID: 36445410
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
Curti BD; Richards J; Hyngstrom JR; Daniels GA; Faries M; Feun L; Margolin KA; Hallmeyer S; Grose M; Zhang Y; Li A; Andtbacka RHI
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564126
[TBL] [Abstract][Full Text] [Related]
3. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Rudin CM; Pandha HS; Zibelman M; Akerley WL; Harrington KJ; Day D; Hill AG; O'Day SJ; Clay TD; Wright GM; Jennens RR; Gerber DE; Rosenberg JE; Ralph C; Campbell DC; Curti BD; Merchan JR; Ren Y; Schmidt EV; Guttman L; Gupta S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36669791
[TBL] [Abstract][Full Text] [Related]
4. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Andtbacka RHI; Curti B; Daniels GA; Hallmeyer S; Whitman ED; Lutzky J; Spitler LE; Zhou K; Bommareddy PK; Grose M; Wang M; Wu C; Kaufman HL
J Clin Oncol; 2021 Dec; 39(34):3829-3838. PubMed ID: 34464163
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.
Lutzky J; Sullivan RJ; Cohen JV; Ren Y; Li A; Haq R
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6059-6066. PubMed ID: 36651961
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
Tran TQ; Grein J; Selman M; Annamalai L; Yearley JH; Blumenschein WM; Sadekova S; Chackerian AA; Phan U; Wong JC
Mol Ther Oncol; 2024 Jun; 32(2):200807. PubMed ID: 38745749
[TBL] [Abstract][Full Text] [Related]
10. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
11. Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Gandhi S; Pandey MR; Attwood K; Ji W; Witkiewicz AK; Knudsen ES; Allen C; Tario JD; Wallace PK; Cedeno CD; Levis M; Stack S; Funchain P; Drabick JJ; Bucsek MJ; Puzanov I; Mohammadpour H; Repasky EA; Ernstoff MS
Clin Cancer Res; 2021 Jan; 27(1):87-95. PubMed ID: 33127652
[TBL] [Abstract][Full Text] [Related]
12. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
13. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
14. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Rahma OE; Tyan K; Giobbie-Hurder A; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Hathaway E; Cunningham R; Manos M; Severgnini M; Rodig S; Stephen Hodi F
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264434
[TBL] [Abstract][Full Text] [Related]
15. Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.
Shoushtari AN; Olszanski AJ; Nyakas M; Hornyak TJ; Wolchok JD; Levitsky V; Kuryk L; Hansen TB; Jäderberg M
Clin Cancer Res; 2023 Jan; 29(1):100-109. PubMed ID: 36112545
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Olson DJ; Eroglu Z; Brockstein B; Poklepovic AS; Bajaj M; Babu S; Hallmeyer S; Velasco M; Lutzky J; Higgs E; Bao R; Carll TC; Labadie B; Krausz T; Zha Y; Karrison T; Sondak VK; Gajewski TF; Khushalani NI; Luke JJ
J Clin Oncol; 2021 Aug; 39(24):2647-2655. PubMed ID: 33945288
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
[Next] [New Search]
